TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2429.
Locate Jan Aushadhi KendraClinical Overview
Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, preferably 30 to 60 minutes before meals or 1-2 hours after food. High-protein foods (meat, dairy, eggs) interfere with absorption; protein intake should be separated from dosing if motor fluctuations occur. Maintain strict timing of doses.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, anorexia, dyskinesias (choreoathetotic movements), dizziness, orthostatic hypotension, vivid dreams, insomnia. Rare/Severe: Hallucinations, psychosis, impulse control disorders (gambling, hypersexuality), sudden sleep onset episodes, and depression.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated with non-selective MAOIs and in patients with narrow-angle glaucoma or suspicious undiagnosed skin lesions (melanoma). Long-term therapy is associated with motor complications (wearing-off, on-off phenomenon, peak-dose dyskinesia). Taper gradually.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Levodopa 100mg + Carbidopa 25mg Tablets
Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.
Carbidopa 10mg + Levodopa 100mg Tablets
Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.
Levodopa 100mg + Carbidopa 25mg + Entacapone 200mg Tablets
Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").
Levodopa 150mg + Carbidopa 37.5mg + Entacapone 200mg Tablets
Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").